Navigation Links
UnderPenetrated Latin American Varicose Vein Treatment Device Market Will Grow Rapidly Through 2021
Date:6/20/2013

TORONTO, June 20, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the Latin American varicose vein treatment device market is severely underpenetrated, with less than 5 percent of the eligible patient pool estimated to have undergone treatment in 2012. This can be primarily attributed to the elective nature of these procedures; governments and patients will continue to place more focus on treating life-threatening conditions or those that would more severely impact their quality of life. Nonetheless, as the Latin American economy strengthens, patients will have more disposable income and greater access to insurance, which will spur rapid adoption of varicose vein treatments through 2021.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

When varicose veins are treated, many Latin Americans will continue to opt for the least expensive option: surgical vein stripping. Although this procedure is both invasive and painful, it is often covered by public or private insurance, unlike many other alternatives such as endovenous ablation. This is important in the cost-conscious environment in Latin America.

Competitors have therefore struggled to earn adoption of more expensive devices that can be used for less painful varicose vein treatments. For example, manufacturers of endovenous laser ablation devices have experienced the highest rates of adoption in Argentina, but are struggling in other Latin American markets. However, this difficulty is even more pronounced in the sclerotherapy market.

"Sclerotherapy is popular, and getting even more popular," said MRG Analyst Tonya Martin. "However, competitors have been unable to harness this popularity due to difficulties in gaining approval for sclerosants, poor distribution networks and a lack of consensus on the appropriate agent to be used in each sclerotherapy treatment. As a result, most Latin American physicians are using low-cost off-brand sclerosants or importing agents illegally."

Because sclerotherapy accounts for more than half of varicose vein treatment volumes in Latin America, spurring adoption of legal and approved sclerosants is a key opportunity for competitors going forward.

Millennium Research Group's Latin American Markets for Varicose Vein Treatment Devices 2013 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for endovenous ablation devices and surgical stripping devices in Argentina, Brazil, Colombia and Mexico. Procedure volumes are also provided for sclerotherapy and phlebectomy treatments. Supplemental country coverage is also available for Chile, Peru and Venezuela, as well as in aggregate for the rest of the Latin American countries.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net

 

 


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
2. Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
3. Mega Trends Foster Investment, Innovation and Expansion in Latin America, Finds Frost & Sullivan
4. Latin America Medical Device Market Reports
5. Pi2 Solutions 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia
6. OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons
7. Economic Growth In Latin America Fueling Strong Revenue Growth For Interventional Cardiology Devices
8. For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
9. Olympus Introduces the Worlds Only Articulating HD 3D Laparoscopic Surgical Video System
10. Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
11. Latin American Electronic Medical Record Market: Key Trends and Forecasts until 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
Breaking Medicine Technology:
(Date:4/26/2017)... St. Louis, Missouri (PRWEB) , ... April 26, ... ... optimal cost, quality and clinical outcomes, today released the podcast, “Make Plans ... Act in bringing value-based payment into the physician's office and how physicians and ...
(Date:4/26/2017)... N.J. (PRWEB) , ... April 26, 2017 , ... ... Inc. in Hackensack, N.J. has been honored by Enterprising Women magazine as ... that recognizes the world’s top women business owners. Winners have demonstrated that they ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant ... produce more and better food, with fewer resources. It highlights the business’ principles, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , ... . This new addition to the Mirroring360 product family combines device screen mirroring ... Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror app ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... attempts to compare student test score performance for the 2015-16 school year across ... state’s voucher programs. Though it highlights important patterns in student test score performance, ...
Breaking Medicine News(10 mins):